2019 Phoenix Patient Conference: New Biologicals for Asthma
Matthew A. Rank, MD, Chair, Division of Allergy and Immunology
Mayo Clinic Arizona
| Introduction of today’s topic: the new biological drugs used for asthma treatment. | 00:28 |
| Presentation overview: what it means to be biological, clinical needs and uses, asthma biologicals currently available, and their role in vasculitis. | 03:11 |
| Why do we need biological drugs for asthma? | 05:37 |
| Current asthma biological drugs: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. | 08:15 |
| How do we decide about using asthma biologics? | 12:23 |
| What about the costs of biologic drugs? | 16:30 |
| How this is all related to vasculitis: drug approvals, key studies, patients in remission, and lower dosages. | 19:17 |
| Summary slide: 5 asthma biologics now; most people with asthma won’t need them; EGPA is most relevant to mepolizumab; several additional asthma biologics in the pipeline; big need for comparative studies; not clear if biologics other than mepolizumab will be used for vasculitis. | 21:30 |
| Closing with a story about how hard the struggle is to get these medications for patients. | 22:37 |
